Mill Creek Capital Advisors LLC Purchases Shares of 90,908 Adagene Inc. (NASDAQ:ADAG)

Mill Creek Capital Advisors LLC acquired a new position in Adagene Inc. (NASDAQ:ADAG) during the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 90,908 shares of the company’s stock, valued at approximately $202,000.

Separately, Catalina Capital Group LLC bought a new stake in Adagene during the second quarter worth approximately $51,000. 9.51% of the stock is currently owned by institutional investors and hedge funds.

Adagene Price Performance

Shares of ADAG opened at $2.16 on Monday. The business’s 50-day moving average price is $2.58 and its 200 day moving average price is $2.64. Adagene Inc. has a 1-year low of $1.33 and a 1-year high of $4.38.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Adagene in a report on Wednesday, September 18th.

Adagene Profile

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.